Researchers have confirmed that remotely administered digital cognitive assessments can detect subtle cognitive decline linked to early Alzheimer’s disease (AD) within just 30 weeks. This breakthrough offers a rapid, scalable tool for monitoring disease progression and evaluating therapeutic interventions.
Conventional neuropsychological assessments often require years to capture meaningful changes due to the slow nature of cognitive decline. To overcome this latency, investigators analyzed data from 202 adults aged 52-85. The cohort included 152 cognitively unimpaired individuals and 50 with mild cognitive impairment (MCI), a known precursor to dementia.
Participants completed self-administered digital memory tasks from home, focusing on object precision, associative memory, and familiarity-dependent memory. Over the 30-week period, those with MCI exhibited significantly greater decline in familiarity-dependent memory compared to unimpaired peers.
The study further correlated these digital findings with beta-amyloid (Aβ) biomarkers. Among MCI participants with available biomarker data, Aβ-positive individuals showed markedly faster deterioration in both object memory precision and familiarity-dependent memory than their Aβ-negative counterparts.
Critically, the short-term changes detected via remote testing aligned with cognitive decline measured through traditional annual in-person assessments over several years. This validation suggests that unsupervised digital tools capture clinically relevant trajectories, enabling more efficient evaluation of treatment effects and earlier identification of at-risk patients.